Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)

Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials

Samantha Meltzer‐Brody, Helen Colquhoun, Robert Riesenberg et al. · The Lancet · 2018 · 782 citations

Medicine, Pharmacology, Psychiatry +8

Economic and Health Predictors of National Postpartum Depression Prevalence: A Systematic Review, Meta-analysis, and Meta-Regression of 291 Studies from 56 Countries

Jennifer Hahn‐Holbrook, Taylor Cornwell-Hinrichs, Itzel Anaya · Frontiers in Psychiatry · 2018 · 640 citations · Full text

Public Health, Maternal Health, Population Health Sciences +13

Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial

Stephen Kanes, Helen Colquhoun, Handan Gunduz‐Bruce et al. · The Lancet · 2017 · 476 citations

Medicine, Pharmacology, Psychiatry +11

Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery

G. Niklas Norén, Johan Hopstadius, Andrew Bate · Statistical Methods in Medical Research · 2011 · 319 citations · Full text

Public Health, Biostatistics, Clinical Epidemiology +11

Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source

Yoshihiro Noguchi, Tomoya Tachi, Hitomi Teramachi · Briefings in Bioinformatics · 2021 · 259 citations

Pharmacy, Pharmacology, Clinical Pharmacology +16